123 related articles for article (PubMed ID: 35777700)
21. Survivin expression at the mRNA level in tumors and the protein concentration in the serum and peritoneal fluid in patients with serous ovarian tumors.
Kruszniewska-Rajs C; Smycz-Kubanska M; Strzalka-Mrozik B; Strzelczyk J; Szanecki W; Witek A; Gola J; Mielczarek-Palacz A
Ginekol Pol; 2023; 94(6):435-441. PubMed ID: 36929784
[TBL] [Abstract][Full Text] [Related]
22. Genetic alteration and immunohistochemical staining patterns of ovarian high-grade serous adenocarcinoma with special emphasis on p53 immnnostaining pattern.
Lee SH; Kim H; Kim WY; Han HS; Lim SD; Kim WS; Kim S; Hwang TS
Pathol Int; 2013 May; 63(5):252-9. PubMed ID: 23714252
[TBL] [Abstract][Full Text] [Related]
23. [Relationship between P53 Protein Expression and Prognosis of Advanced Ovarian Serous Adenocarcinoma].
Zuo J; Song Y; Li Z; Wu LY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2016 Apr; 38(2):169-74. PubMed ID: 27181893
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of nuclear factor-kappa B enhances the tumor growth of ovarian cancer cell line derived from a low-grade papillary serous carcinoma in p53-independent pathway.
Xiao X; Yang G; Bai P; Gui S; Nyuyen TM; Mercado-Uribe I; Yang M; Zou J; Li Q; Xiao J; Chang B; Liu G; Wang H; Liu J
BMC Cancer; 2016 Aug; 16():582. PubMed ID: 27484466
[TBL] [Abstract][Full Text] [Related]
25. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J
Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744
[TBL] [Abstract][Full Text] [Related]
26. A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging.
Skírnisdóttir I; Seidal T; Sorbe B
Int J Gynecol Cancer; 2004; 14(2):259-70. PubMed ID: 15086725
[TBL] [Abstract][Full Text] [Related]
27. KLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancer.
De Donato M; Babini G; Mozzetti S; Buttarelli M; Ciucci A; Arduini G; De Rosa MC; Scambia G; Gallo D
J Exp Clin Cancer Res; 2020 Nov; 39(1):265. PubMed ID: 33250051
[TBL] [Abstract][Full Text] [Related]
28. P53 and TLR4 expression are prognostic markers informing progression free survival of advanced stage high grade serous ovarian cancer.
Bates M; Mullen D; Lee E; Costigan D; Heron EA; Kernan N; Barry-O'Crowley J; Martin C; Keegan H; Malone V; Brooks RD; Brooks DA; Logan JM; Martini C; Selemidis S; McFadden J; O'Riain C; Spillane CD; Gallagher MF; McCann A; O'Toole S; O'Leary JJ
Pathol Res Pract; 2024 Jan; 253():155020. PubMed ID: 38103365
[TBL] [Abstract][Full Text] [Related]
29. Molecular characterization of 103 ovarian serous and mucinous tumors.
Vereczkey I; Serester O; Dobos J; Gallai M; Szakács O; Szentirmay Z; Tóth E
Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228
[TBL] [Abstract][Full Text] [Related]
30. Expression of p53, p21WAF1/CIP1, p16INK4A and Ki-67 proteins in serous ovarian tumors.
Buchynska LG; Nesina IP; Yurchenko NP; Bilyk OO; Grinkevych VN; Svintitsky VS
Exp Oncol; 2007 Mar; 29(1):49-53. PubMed ID: 17431389
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma.
Chiesa-Vottero AG; Malpica A; Deavers MT; Broaddus R; Nuovo GJ; Silva EG
Int J Gynecol Pathol; 2007 Jul; 26(3):328-33. PubMed ID: 17581420
[TBL] [Abstract][Full Text] [Related]
32. Association of expression of kruppel-like factor 4 and kruppel-like factor 5 with the clinical manifestations of breast cancer.
Chen CJ; Lin SE; Lin YM; Lin SH; Chen DR; Chen CL
Pathol Oncol Res; 2012 Apr; 18(2):161-8. PubMed ID: 21674249
[TBL] [Abstract][Full Text] [Related]
33. [Expression and significance of microRNAs in the p53 pathway in ovarian cancer cells and serous ovarian cancer tissues].
Zhang Q; He XJ; Ma LP; Li N; Yang J; Cheng YX; Cui H
Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):885-90. PubMed ID: 22340095
[TBL] [Abstract][Full Text] [Related]
34. [The immunohistochemical features of ovarian serous adenocarcinoma cells, which determine a disease course and survival rates in patients].
Pozharissky KM; Raskin GA; Vinokurov VL; Yurkova LE; Mukhina MS
Arkh Patol; 2015; 77(1):38-40. PubMed ID: 25868367
[TBL] [Abstract][Full Text] [Related]
35. Combination of serum hCG beta and p53 tissue expression defines distinct subgroups of serous ovarian carcinoma.
Vartiainen J; Lassus H; Lehtovirta P; Finne P; Alfthan H; Butzow R; Stenman UH
Int J Cancer; 2008 May; 122(9):2125-9. PubMed ID: 18098286
[TBL] [Abstract][Full Text] [Related]
36. Aldehyde dehydrogenase 1A1 (ALDH1A1) expression by immunohistochemistry is associated with chemo-refractoriness in patients with high-grade ovarian serous carcinoma.
Roy M; Connor J; Al-Niaimi A; Rose SL; Mahajan A
Hum Pathol; 2018 Mar; 73():1-6. PubMed ID: 28851663
[TBL] [Abstract][Full Text] [Related]
37. Association of p21, p21 p27 and p21 p53 status to histological subtypes and prognosis in low-stage epithelial ovarian cancer.
Skirnisdottir I; Seidal T
Cancer Genomics Proteomics; 2013; 10(1):27-34. PubMed ID: 23382584
[TBL] [Abstract][Full Text] [Related]
38. The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy.
Protopapas A; Diakomanolis E; Bamias A; Milingos S; Markaki S; Papadimitriou C; Dimopoulos AM; Michalas S
Eur J Gynaecol Oncol; 2004; 25(2):225-9. PubMed ID: 15032288
[TBL] [Abstract][Full Text] [Related]
39. [Evaluation of two-tier grading system and significance of p53 protein over-expression in ovarian serous carcinoma].
Lin J; Du J; Zhang CY; Xie QT; Zhang B; Liu CR
Zhonghua Bing Li Xue Za Zhi; 2010 Oct; 39(10):655-60. PubMed ID: 21176529
[TBL] [Abstract][Full Text] [Related]
40. High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the "SET" feature of high-grade serous carcinoma to the "STEM" feature.
Hatano Y; Tamada M; Asano N; Hayasaki Y; Tomita H; Morishige KI; Hara A
Diagn Pathol; 2019 Jan; 14(1):4. PubMed ID: 30636633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]